Dr. Michael B. Collins, M.D.
Interventional Cardiology (Interventional Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- New York Medical College (1975)
- Years since graduation
- 51
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 125
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1975Medical school: New York Medical College
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Interventional Cardiology Physician primary
NY license 130443 -
Cardiovascular Disease Physician
NY license 130443
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
Medical groups
- Trustees of Columbia University in The City of New York (2,296 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 125
- Services billed
- 463
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 117 | 114 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 79 | 78 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 46 | 46 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 41 | 14 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 20 | 20 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 15 | 15 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, each additional vessel | 15 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clopidogrel (clopidogrel bisulfate) Other prescribers in New York, NY | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 23 payments worth $780 in total to this clinician.
| Heartflow, Inc. | $162 |
|---|---|
| Novartis Pharmaceuticals Corporation | $143 |
| Asahi Intecc USA, Inc. | $142 |
| Abiomed | $142 |
| Regeneron Pharmaceuticals, Inc. | $115 |
| Alnylam Pharmaceuticals Inc. | $29.50 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $24.00 |
| Bridgebio Pharma, Inc. | $22.54 |
| Food and Beverage | $780 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $78,965 in research payments for these studies, mostly to the institutions running them.
- Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
Abbott Laboratories · Active, not recruiting · NCT03108456 - BIOFLOW-VII
Biotronik Inc. - A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)
Boston Scientific Corporation · Active, not recruiting · NCT04647253
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.